These genes exhibited high drug–gene interaction scores and hazard ratios, suggesting promising targets for future therapeutic development aimed at modulating the immunosuppressive function of SPP1+ TAMs in HCC (Figure 7G, Table S7). This evidence concerns the gene SPP1 and hepatocellular carcinoma.